1-6 of 6
Steffen Luntz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Hartmut Goldschmidt, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Michael Hundemer, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc-Steffen Raab, Martin Hoffmann, Katja C. Weisel, Hans Salwender, Elias K. Mai
Journal: Blood
Blood (2024) 144 (Supplement 1): 769.
https://doi.org/10.1182/blood-2024-193308
Published: 2024
Journal Articles

Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Anne-Valérie Keller, Marina Hajiyianni, Eileen Kurre, Elias Karl Mai, Uta Bertsch, Axel Benner, Steffen Luntz, Marc-Steffen Raab, Britta Besemer, Christian Sebastian Michel, Roland Schroers, Roland Fenk, Hans Salwender, Igor Wolfgang Blau, Mathias Hänel, Christoph Mann, Hartmut Goldschmidt
Journal: Blood
Blood (2024) 144 (Supplement 1): 5140.
https://doi.org/10.1182/blood-2024-194188
Published: 2024
Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Elias K. Mai, Hans Salwender, Michael Hundemer, Uta Bertsch, Ema Pozek, Axel Benner, Roland Fenk, Britta Besemer, Christine Hanoun, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Lisa Leypoldt, Bernhard Heilmeier, Stefanie Huhn, Sabine Vogel, Christof Scheid, Igor Wolfgang Blau, Steffen Luntz, Niels Weinhold, Tobias A.W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Evgenii Shumilov, Wolfgang Knauf, Christian Sebastian Michel, Thomas Geer, Hendrik Riesenberg, Christoph Lutz, Marc S. Raab, Martin Hoffmann, Katja C. Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2024) 144 (Supplement 1): 364.
https://doi.org/10.1182/blood-2024-194768
Published: 2024
Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias K. Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Hänel, Ivana von Metzler, Lindemann Hans W., Christof Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel, Hartmut Goldschmidt
Journal: Blood
Blood (2023) 142 (Supplement 1): 782.
https://doi.org/10.1182/blood-2023-178835
Published: 2023
Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Hartmut Goldschmidt, MD, Marc-A. Baertsch, MD, Jana Schlenzka, MD, Natalia Becker, PhD, Habermehl Christina, PhD, Thomas Hielscher, Marc S Raab, MD, Jens Hillengass, MD, Carsten Müller-Tidow, MD, Steffen Luntz, MD, Anna Jauch, PhD, Peter Brossart, MD, Martin Goerner, MD, Stefan A Klein, MD, Martin Schmidt-Hieber, MD PhD, Peter Reimer, MD, Ullrich Graeven, MD, Roland Fenk, MD PhD, Mathias Haenel, MD, Hans Martin, MD, Hans-Walter Lindemann, MD, Christoph Scheid, MD, Axel Nogai, MD, Hans Jürgen Salwender, MD, Richard Noppeney, MD, Katja Weisel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 253.
https://doi.org/10.1182/blood-2018-99-111203
Published: 2018
Journal Articles

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Marc-A. Baertsch, MD, Jana Schlenzka, MD, Habermehl Christina, PhD, Thomas Hielscher, Marc S Raab, MD, Jens Hillengass, MD, Carsten Müller-Tidow, MD, Steffen Luntz, MD, Anna Jauch, PhD, Peter Brossart, MD, Martin Goerner, MD, Stefan A Klein, MD, Martin Schmidt-Hieber, MD PhD, Peter Reimer, MD, Ullrich Graeven, MD, Roland Fenk, MD PhD, Mathias Haenel, MD, Hans Martin, MD, Hans-Walter Lindemann, MD, Christoph Scheid, MD, Axel Nogai, MD, Hans Jürgen Salwender, MD, Richard Noppeney, MD, Katja Weisel, MD, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 254.
https://doi.org/10.1182/blood-2018-99-119762
Published: 2018